BMS 275183

Overview

BMS 275183 is a potent, orally active analogue of Paclitaxel ( HY-B0015 ). BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel -resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein . BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Microtubule/Tubulin | Products > Signaling Pathways > P-glycoprotein

Product Information

• Catalog No.: HY-106219
• CAS No.: 355113-98-3
• Molecular Formula: C43H59NO16
• Molecular Weight: 845.93
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source